Evaluating T-Cell Therapies in First-Line Multiple Myeloma Treatment
Aislinn Antrim
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers.
There are limited randomized data on studies that focus on T-cell–directed therapies in the first-line setting for multiple myeloma. However, the ongoing CARTITUDE-5 and CARTITUDE-6 studies are comparing chimeric antigen receptor (CAR) T-cell therapies with traditional treatments, said Rahul Banerjee, MD, FACP, assistant professor for the Division of Hematology and Oncology at the University of Washington.
Banerjee attended the annual
The
Banerjee also addressed the
"Bispecifics are also being explored in the front-line setting. There are several studies that have been looking at this;
Banerjee explains the purpose of MajesTEC-7 was to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide and talquetamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone.
Additionally, he mentions the
"Even if tomorrow, teclistamab were to be approved for front-line therapy in any subset of patients, I would hazard a guess that 90% of Americans do not live within 30 minutes of a bispecific-capable center."
Banerjee concludes the interview by recognizing the specific outpatient dosing they have access to but how this falls short on a global scale.
"I do want to put a very clear note of caution there that we need to look before we leap into this world of BCMA [B-cell maturation antigen] as front-line therapy."
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
September 17th 2025
- Cost-Effectiveness of Varying Weight Loss Interventions: Elena Losina, PhD
September 17th 2025
- Transforming Addiction Care: From Stigma to Support
September 16th 2025